Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the USA on 26th November 2019. The patent number is 10,488,530.
Related Posts
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
TRUEinvivo wins Business Innovation of the Year Award for DOSEmapper™ technology, revolutionizing radiotherapy safety.
Dr. Shakar Jafari discusses Women in Innovation and cancer care on Huffington Post.
TRUEinvivo's 2018 achievements include prototype development, patent filings, fundraising, multiple awards, and market expansion, setting the stage for a busy 2019.
